China Dna Diagnostics Market Size & Outlook, 2023-2030

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna diagnostics market will help companies and investors design strategic landscapes.

Pcr-based diagnostics was the largest segment with a revenue share of 49.68% in 2023. Horizon Databook has segmented the China dna diagnostics market based on pcr-based diagnostics, ngs dna diagnosis, in-situ hybridization diagnostics, microarrays-based diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.

In China, there has been a significant shift in death rates over the past 40 years from infectious diseases to NCDs. DNA testing can identify pathogens with high precision, enabling rapid and accurate diagnosis of infections like bacterial, viral, & fungal diseases. This helps in tailoring the right treatment quickly. The main causes of this change have been risk factors like nutrition, physical inactivity, and smoking.

Due to socioeconomic progress and demographic changes, China has experienced significant shifts in its mortality patterns over the past 40 years, moving from infectious diseases to NCDs. This shift has been fueled by the widespread nature of risk factors, such as alcohol misuse, smoking, poor food, and physical inactivity; as a result, the leading causes of mortality in this country are now diabetes, cancer, Cardiovascular Disease (CVD), and Chronic Respiratory Diseases (CRD). Compared to other countries and regions with comparable levels of social development, China has a greater prevalence of diabetes, cancer, CVDs, and renal disease.

These NCDs are responsible for 84.9% of the disease burden (disability-adjusted life years) and 88.5% of all deaths. The aging population has resulted in an increase in falls and aging-related disease. More resilient healthcare systems are necessary to manage comorbidities and chronic impairments in the face of increasing life expectancies and technological advancements. Many cancers and chronic diseases are associated with specific genetic mutations.